Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is headquartered in Petaluma, US
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Office Locations
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) has offices in Petaluma and Herten
Petaluma, US (HQ)
1129 N Mc Dowell Blvd
Herten, NL
6049 Lx Herten/Roermond
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Data and Metrics
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financial Metrics
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s revenue was reported to be $12.8 m in FY, 2017 which is a 15% decrease from the previous period.
USD
Revenue (FY, 2017) | 12.8 m |
Revenue growth (FY, 2016 - FY, 2017), % | (15%) |
Gross profit (FY, 2017) | 5.7 m |
Gross profit margin (FY, 2017), % | 44% |
Net income (FY, 2017) | 9.3 m |
EBIT (FY, 2017) | (13 m) |
Market capitalization (05-Dec-2016) | 20.9 m |
Closing share price (05-Dec-2016) | 4.9 |
Cash (31-Mar-2017) | 17.5 m |
EV | 3.5 m |
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s current market capitalization is $20.9 m.
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Revenue | 13.7 m | 13.9 m | 15.1 m | 12.8 m |
Revenue growth, % | 1% | 9% | (15%) | |
Cost of goods sold | 5.3 m | 6.6 m | 7.9 m | 7.2 m |
Gross profit | 8.4 m | 7.3 m | 7.2 m | 5.7 m |
Gross profit Margin, % | 61% | 53% | 48% | 44% |
R&D expense | 1.6 m | |||
General and administrative expense | 17.1 m | |||
Operating expense total | 14.4 m | 13.9 m | 17.4 m | 18.6 m |
EBIT | (6.1 m) | (6.7 m) | (10.2 m) | (13 m) |
EBIT margin, % | (44%) | (48%) | (67%) | (101%) |
Interest expense | 1.1 m | 3 k | 3 k | (3 k) |
Interest income | 1 k | 1 k | 2 k | 22 k |
Pre tax profit | (12.9 m) | |||
Income tax expense | 4.3 m | |||
Net Income | 3.7 m | (8.2 m) | (10.2 m) | 9.3 m |
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Cash | 5.5 m | 6.1 m | 7.5 m | 17.5 m |
Accounts Receivable | 1.8 m | 1.5 m | 2.3 m | 2.1 m |
Inventories | 647 k | 592 k | 1.5 m | 2.2 m |
Current Assets | 9.5 m | 9.6 m | 12.9 m | 22.6 m |
PP&E | 971 k | 795 k | 850 k | 1.2 m |
Total Assets | 20.8 m | 15 m | 13.8 m | 25.5 m |
Accounts Payable | 736 k | 932 k | 1.3 m | 1.3 m |
Total Debt | 123 k | |||
Current Liabilities | 7.6 m | 2.6 m | 3.6 m | 3.3 m |
Total Liabilities | 4 m | |||
Additional Paid-in Capital | 149.1 m | 157.8 m | 166.4 m | 168.7 m |
Retained Earnings | (134 m) | (142.2 m) | (152.4 m) | (143.1 m) |
Total Equity | 12.1 m | 12.1 m | 10.1 m | 21.4 m |
Debt to Equity Ratio | 0 x | |||
Debt to Assets Ratio | 0 x | |||
Financial Leverage | 1.7 x | 1.2 x | 1.4 x | 1.2 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Net Income | 3.7 m | (8.2 m) | (10.2 m) | 9.3 m |
Depreciation and Amortization | 284 k | 253 k | 244 k | 248 k |
Accounts Receivable | (88 k) | 40 k | (1.3 m) | 34 k |
Inventories | (126 k) | (627 k) | (382 k) | (675 k) |
Accounts Payable | 848 k | 222 k | 429 k | (58 k) |
Cash From Operating Activities | (4.9 m) | (6.7 m) | (8.7 m) | (8.2 m) |
Purchases of PP&E | (504 k) | (139 k) | (345 k) | (394 k) |
Cash From Investing Activities | (445 k) | 875 k | 4.2 m | 18.2 m |
Long-term Borrowings | (1.6 m) | (176 k) | (119 k) | (130 k) |
Cash From Financing Activities | 2.9 m | 6.6 m | 6 m | (32 k) |
Interest Paid | 195 k | 3 k | 3 k | 3 k |
| USD | Y, 2017 |
|---|---|
EV/EBIT | -0.3 x |
EV/CFO | -0.4 x |
Revenue/Employee | 337.5 k |
Financial Leverage | 1.2 x |
